| アブストラクト | BACKGROUND: Prostate cancer is among the most prevalent malignancies worldwide, and cardiovascular disease (CVD) is a major non-cancer cause of death in affected patients. Androgen deprivation therapy (ADT), a mainstay treatment, has raised concerns about cardiotoxicity, yet the CVD risks of individual ADT agents remain unclear. OBJECTIVES: To assess cardiovascular adverse events (AEs) associated with specific ADT drugs using data from the U.S. FDA Adverse Event Reporting System (FAERS). METHODS: AE reports related to ADT drugs were extracted from FAERS (Q1 2004-Q3 2024). Disproportionality analyses-including Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR)-were conducted to identify significant cardiovascular safety signals. RESULTS: Different ADT agents exhibited distinct cardiovascular AE profiles. Some drugs were linked to a broader range of CVD-related AEs, while others had more limited associations. CONCLUSIONS: ADT agents demonstrate heterogeneous cardiotoxicity profiles. These findings emphasize the need for individualized treatment strategies, particularly in patients with pre-existing CVD risks, and may aid clinicians in balancing cancer control with cardiovascular safety. |
|---|
| ジャーナル名 | Cancer medicine |
|---|
| Pubmed追加日 | 2025/12/22 |
|---|
| 投稿者 | Wang, Wei; Dong, Zirui; Hong, Baoan; Guan, Xin; Wang, Yuxuan; Sun, Zhipeng; Miao, Qi; Zhang, Ning |
|---|
| 組織名 | Department of Urology, Beijing Anzhen Hospital, Capital Medical University,;Beijing, P. R. China.;Department of Urology, Union Hospital, Tongji Medical College, Huazhong;University of Science and Technology, Wuhan, Hubei, P. R. China.;Department of Nuclear Medicine, First Hospital of Shanxi Medical University,;Shanxi Medical University, Taiyuan, Shanxi, P. R. China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41423663/ |
|---|
